Literature DB >> 189709

Observations on the postoperative tumor growth behavior of certain islet cell tumors.

R M Zollinger, E W Martin, L C Carey, J Sparks, J P Minton.   

Abstract

Over a period of 21 years 39 patients with gastrinoma were surgically treated. Thirty-three patients had total gastrectomy with two postoperative deaths, and 6 patients had a lesser procedure. The postoperative fasting gastrin levels remained elevated and did not always indicate the extent of tumor involvement. Further mobilization of tumor gastrin by provocative infusion of calcium gluceptate, 15 mg/kg of body weight, should be carried out routinely. A hepatic angiogram should be considered when the gastrin levels exceed 1,000 picograms per ml. Chemotherapy consisting of Tubercidin, Streptozotocin and 5-Fluorouracil was given to 5 patients with extensive gastrinoma. All patients felt better and gained from three to 35 pounds in weight. Since 60% of the patients died or have definite evidence of tumor activity it is assumed that the tumor growth was not inhibited and that it is malignant. Approximately 40% of the patients seem to do well despite modest elevations in gastrin levels suggesting that the retained tumor could be considered benign.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 189709      PMCID: PMC1345457          DOI: 10.1097/00000658-197610000-00016

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  11 in total

1.  Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas.

Authors:  R M ZOLLINGER; E H ELLISON
Journal:  Ann Surg       Date:  1955-10       Impact factor: 12.969

2.  Letter: Treatment of "pancreatic cholera".

Authors:  S R Siegel; F M Muggia
Journal:  N Engl J Med       Date:  1975-07-24       Impact factor: 91.245

3.  Pancreatic cholera: benefical effects of treatment with streptozotocin.

Authors:  C R Kahn; A G Levy; J D Gardner; J V Miller; P Gorden; P S Schein
Journal:  N Engl J Med       Date:  1975-05-01       Impact factor: 91.245

4.  Natural history and experience with diagnosis and treatment of the Zollinger-Ellison syndrome.

Authors:  J C Thompson; D D Reeder; H V Villar; H R Fender
Journal:  Surg Gynecol Obstet       Date:  1975-05

5.  Effect of total gastrectomy on the Zollinger-Ellison tumor: observations by second-look procedures.

Authors:  S R Friesen
Journal:  Surgery       Date:  1967-10       Impact factor: 3.982

6.  Treatment of multiple-hormone-producing malignant islet-cell tumour with streptozotocin.

Authors:  I M Murray-Lyon; A L Eddleston; R Williams; M Brown; B M Hogbin; A Bennett; J C Edwards; K W Taylor
Journal:  Lancet       Date:  1968-10-26       Impact factor: 79.321

7.  Prognostic implications of calcium-mediated gastrin levels in the ulcerogenic syndrome.

Authors:  L J Sanzenbacher; D R King; R M Zollinger
Journal:  Am J Surg       Date:  1973-01       Impact factor: 2.565

8.  Effect of secretin on circulating gastrin.

Authors:  J C Thompson; D D Reeder; H H Bunchman; H D Becker; E N Brandt
Journal:  Ann Surg       Date:  1972-09       Impact factor: 12.969

9.  Unusual effect of secretin on serum gastrin, serum calcium, and gastric acid secretion in a patient with suspected Zollinger-Ellison syndrome.

Authors:  J I Isenberg; J H Walsh; E Passaro; E W Moore; M I Grossman
Journal:  Gastroenterology       Date:  1972-04       Impact factor: 22.682

10.  Letter: Streptozotocin in the Zollinger-Ellison syndrome.

Authors:  L Sadoff; D Franklin
Journal:  Lancet       Date:  1975-09-13       Impact factor: 79.321

View more
  17 in total

1.  Surgery increases survival in patients with gastrinoma.

Authors:  Jeffrey A Norton; Douglas L Fraker; H R Alexander; Fathia Gibril; David J Liewehr; David J Venzon; Robert T Jensen
Journal:  Ann Surg       Date:  2006-09       Impact factor: 12.969

2.  Recurrent gastrinoma in the mesentery 19 years after primary resection.

Authors:  Keiko Nishio; Akiyoshi Nishio; Toshikuni Nishikawa; Yoichiro Kobashi; Satoru Matsusue
Journal:  Dig Dis Sci       Date:  2007-04-10       Impact factor: 3.199

3.  Studies with bombesin in man.

Authors:  N Basso; E Lezoche; V Speranza
Journal:  World J Surg       Date:  1979-09-20       Impact factor: 3.352

4.  The use of high-resolution intraoperative ultrasound to localize gastrinomas: an initial report of a prospective study.

Authors:  D T Cromack; J A Norton; B Sigel; T H Shawker; J L Doppman; P N Maton; R T Jensen
Journal:  World J Surg       Date:  1987-10       Impact factor: 3.352

5.  Treatment of patients with pancreatic endocrine tumours using a new long-acting somatostatin analogue symptomatic and peptide responses.

Authors:  S M Wood; M E Kraenzlin; T E Adrian; S R Bloom
Journal:  Gut       Date:  1985-05       Impact factor: 23.059

6.  Clinical significance of glucagon provocation test in the diagnosis of hypergastrinemia.

Authors:  C Nakanome; A Ishimori; Y Goto; T Yamazaki; J Kameyama; I Sasaki; M Inui; Y Furukawa; K Komatsu
Journal:  Gastroenterol Jpn       Date:  1981

7.  Prospective study of gastrinoma localization and resection in patients with Zollinger-Ellison syndrome.

Authors:  J A Norton; J L Doppman; M J Collen; J W Harmon; P N Maton; J D Gardner; R T Jensen
Journal:  Ann Surg       Date:  1986-10       Impact factor: 12.969

Review 8.  Current approach to the management of gastrinoma and insulinoma in adults with multiple endocrine neoplasia type I.

Authors:  M Mignon; P Ruszniewski; P Podevin; L Sabbagh; G Cadiot; D Rigaud; S Bonfils
Journal:  World J Surg       Date:  1993 Jul-Aug       Impact factor: 3.352

9.  Removal of gastrinomas for control of Zollinger-Ellison syndrome.

Authors:  J W Harmon; J A Norton; M J Collin; A G Krudy; T H Shawker; J L Doppman; J d'Avis; R T Jensen
Journal:  Ann Surg       Date:  1984-10       Impact factor: 12.969

10.  Curative resection in Zollinger-Ellison syndrome. Results of a 10-year prospective study.

Authors:  J A Norton; J L Doppman; R T Jensen
Journal:  Ann Surg       Date:  1992-01       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.